Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Antimicrobial Resistance & Infection Control
Published in: Antimicrobial Resistance & Infection Control 1/2018

Open Access 01-12-2018 | Research

Prevalence of extended-spectrum-β-lactamase-producing Enterobacteriaceae: first systematic meta-analysis report from Pakistan

Authors: Samyyia Abrar, Shahida Hussain, Rehan Ahmad Khan, Noor Ul Ain, Hayat Haider, Saba Riaz

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2018

Login to get access

Abstract

Background

South-Asia is known as a hub for multidrug-resistant (MDR) bacteria. Unfortunately, proper surveillance and documentation of MDR pathogens is lacking in Pakistan. The alarming increase in the prevalence of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is a serious problem. From this perspective, we analysed published data regarding ESBL-producing Enterobacteriaceae in different regions of Pakistan.

Methods

A meta-analysis was performed to determine the prevalence of ESBL-producing Enterobacteriaceae in Pakistan. A Web-based search was conducted in electronic databases, including PubMed, Scopus and PakMedi Net (for non-indexed Pakistani journals). Articles published (in either indexed or non-indexed journals) between January 2002 and July 2016 were included in the study. Relevant data were extracted, and statistical analysis was performed using the Metaprop command of STATA version 14.1.

Results

A total of 68 studies were identified from the electronic data base search, and 55 of these studies met our inclusion criteria. Pakistan’s overall pooled proportion of ESBL-producers was 0.40 (95% CI: 0.34–0.47). The overall heterogeneity was significant (I2 = 99.75%, p < 0.001), and significant ES = 0 (Z = 18.41, p < 0.001) was found. OXA, SHV, TEM and CTX-M were the most commonly found gene variants for ESBLs in these studies.

Conclusion

The prevalence of ESBL-producing Enterobacteriaceae is high in Pakistan. Little is known about the annual frequency of ESBLs and their prevalence in different provinces of Pakistan. No data are available regarding ESBL frequency in Baluchistan. This underscores an urgent demand for regular surveillance to address this antimicrobial resistance problem. Surveillance to better understand the annual ESBL burden is crucial to improve national and regional guidelines.
Literature
1.
Kang C-I, Song J-H. Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect Chemother. 2013;45:22–31.PubMedPubMedCentral
2.
Bhatia R, Narain J-P. The growing challenge of antimicrobial resistance in the South-East Asia region-are we losing the battle? Indian J Med Res. 2010;132:482–6.PubMedPubMedCentral
3.
Jean SS, Hsueh P-R. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37:291–5.PubMed
4.
Pitout JD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae. Drugs. 2010;70:313–33.PubMed
5.
Ahmed K, Raja I, Hussain I, Jan M, Nafees M, Jahan Z, Javeed M, Shah G, Latif A. Prevalence of Escherichia coli in suspected urinary tract infected patients and their sensitivity pattern against various Escherichia coli in suspected urinary tract infected patients and their sensitivity pattern against various antibiotics in Gilgit-Baltistan, Pakistan. Pak J Zool. 2014;46:1783–8.
6.
Hafeez R, Aslam M, Mir F, Tahir M, Javaid I, Ajmal A. Frequency of extended spectrum β-lactamase producing gram negative bacilli among clinical isolates. Biomedica. 2009;25:112–5.
7.
Riaz S, Bashir MF. Phenotypic and molecular characterization of plasmid-encoded extended spectrum β-lactamases produced by Escherichia coli and Klebsiella Spp from Lahore, Pakistan. Trop J Pharmaceut Res. 2015;14:1597–604.
8.
Riaz S, Faisal M, Hasnain S. Antibiotic susceptibility pattern and multiple-antibiotic-resistances (MAR) calculation of extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella species in Pakistan. Afri J Biotechnol. 2011;10:6325–31.
9.
Ejaz H, ul-Haq I, Saqib Mahmood S, Zafar A, Javed M-M. Detection of extended-spectrum β-lactamases in Klebsiella pneumoniae: comparison of phenotypic characterization methods. Pak J Med Sci. 2013;29:788–94.
10.
Amin H, Zafar A, Ejaz H, Jameel N-A. Phenotypic characterization of ESBL-producing Enterobacter Cloacae among children. Pak J Med Sci. 2013;29:144–7.PubMedPubMedCentral
11.
Ejaz H, ul-Haq K, Zafa A, Mahmood S, Javed M-M. Urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae. Afric J Biotechnol. 2011;10:16661–6.
12.
Anwar M. Frequency of extended spectrum β-lactamase producing Klebsiella pnumoniae and Escherichia coli isolates. Biomedica. 2007;23:34–8.
13.
Qureshi M, Asif N, Baig S. Evaluation of extended spectrum β-lactamase mediated resistance in Escherichia coli and Klebsiella in urinary tract infection at a tertiary care hospital. Biomedica. 2013;29:78–83.
14.
Khan J, Naz N, AbdEl-Salam N-M, Nayab Nayab N, Tabassum A, Hussain H, Ullah R. ESBL determination and antibacterial drug resistance pattern of Klebsiella pneumoniae amongst patients at PIMS Islamabad. Afric J Tradit Complement Alternv Med. 2015;12:70–7.
15.
Amin A, Ghumro P-B, Hussain S, Hameed A. Prevalence of antibiotic resistance among clinical isolates of Klebsiella pneumoniae isolated from a tertiary care hospital in Pakistan. Malays J Microbiol. 2009;5:81–6.
16.
Habeeb M-A, Sarwar Y, Ali A, Salman M, Haque A. High prevalence of 16S rRNA methylase Rmtb among CTX-M extended-spectrum β-lactamase-producing Klebsiella pneumoniae from Islamabad, Pakistan. Int J Antimicrob Agents. 2013;41:524–6.PubMed
17.
Ali I, Rafaque Z, Ahmed S, Malik S, Dasti J-I. Prevalence of multidrug-resistant uropathogenic Escherichia coli in Potohar region of Pakistan. Asian Pac J Trop Biomed. 2016;6:60–6.
18.
Shafiq M, Rahman H, Qasim M, Ayub N, Hussain S, Khan J, Naeem M. Prevalence of plasmid-mediated Ampc β-Lactamases in Escherichia coli and Klebsiella pneumoniae at tertiary care hospital of Islamabad, Pakistan. Eur J Microbiol Immunol. 2013;3:267–71.
19.
Ilyas M, Shabeer Ahmad MK, Mazhar K, Sajid A. Susceptibility pattern of extended spectrum β-lactamases positive Escherichia coli isolated from a tertiary care hospital of Peshawar, Pakistan. World Appl Sci J. 2014;30:253–7.
20.
Ullah F, Malik S-A, Ahmed J. Antimicrobial susceptibility pattern and ESBL prevalence in Klebsiella pneumoniae from urinary tract infections in the north-west of Pakistan. Afr J Microbiol Res. 2009;3:676–80.
21.
Bari F, Shah H, Wazir R. Frequency and detection of extended spectrum-β-lactamase in Escherichia coli and Klebsiella pneumoniae: a study at lady reading hospital Peshawar. J Postgrad Med Inst. 2015;29:256–9.
22.
Riaz S, Faisal M, Hasnain S. Prevalence and comparison of β-lactamase-producing Escherichia coli and Klebsiella Spp from clinical and environmental sources in Lahore, Pakistan. Afr J Microbiol Res. 2012;6:465–70.
23.
Ndir A, Diop A, Ka R, Faye PM, Dia-Badiane NM, Ndoye B, Astagneau P. Infections caused by extended-spectrum β-lactamases producing Enterobacteriaceae: clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal. Antimicrob Resis Infect Control. 2016;5:13–20.
24.
25.
Xiao Y-H, Giske CG, Wei Z-Q, Shen P, Heddini A, Li L-J. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat. 2011;14:236–50.PubMed
26.
Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35:240–3.PubMed
27.
Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis. 2012;25:371–7.PubMed
28.
Hoban DJ, Bouchillon SK, Hawser SP, Badal RE. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the study for monitoring antimicrobial resistance trends 2002 to 2007. Diagn Microbiol Infect Dis. 2010;66:78–86.PubMed
29.
Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008;62:895–904.PubMedPubMedCentral
30.
Casella T, Rodríguez MM, Takahashi JT, Ghiglione B, Dropa M, Assunção E, Nogueira ML, Lincopan N, Gutkind G, Nogueira MCL. Detection of Bla CTX-M-type genes in complex class 1 integrons carried by Enterobacteriaceae isolated from retail chicken meat in Brazil. Int J Food Microbiol. 2015;197:88–91.PubMed
31.
Chen I-L, Lee C-H, Su L-H, Tang Y-F, Chang S-J, Liu J-W. Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship. PLoS One. 2013;8:E65621.PubMedPubMedCentral
32.
Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10:43–50.PubMed
33.
34.
Kucheria R, Dasgupta P, Sacks S, Khan M, Sheerin N. Urinary tract infections: new insights into a common problem. Postgrad Med J. 2005;81:83–6.PubMedPubMedCentral
35.
David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616–87.PubMedPubMedCentral
36.
Kurutepe S, Surucuoglu S, Sezgin C, Gazi H, Gulay M, Ozbakkaloglu B. Increasing antimicrobial resistance in Escherichia coli isolates from community-acquired urinary tract infections during 1998-2003 in Manisa, Turkey. Jpn J Infect Dis. 2005;58:159–62.PubMed
37.
Song J-H, Jung S-I, Ko KS, Kim NY, Son JS, Chang H-H, Ki HK, Oh WS, Suh JY, Peck KR. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother. 2004;48:2101–7.PubMedPubMedCentral
38.
Hsueh P-R, Hoban DJ, Carmeli Y, Chen S-Y, Desikan S, Alejandria M, Ko W-C, Binh TQ. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in asia-pacific region. J Inf Secur. 2011;63:114–23.
39.
Sunenshine RH, Wright M-O, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007;13:97–103.PubMedPubMedCentral
40.
Yasmin F, Akhtar N, Hameed A. In-vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa. Pak J Pharm Sci. 2013;26:1041–4.PubMed
41.
Okeke IN, Lamikanra A. Export of antimicrobial drugs by west African travelers. J Travel Med. 2003;10:133–5.PubMed
42.
Nyaga VN, Arbyn M, Aerts M. Metaprop : a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72:1–10.
43.
Kumar SG, Adithan C, Harish B, Sujatha S, Roy G, Malini A. Antimicrobial resistance in India: a review. J Nat Sc Biol Med. 2013;4:286–91.
44.
Hannan A, Qamar MU, Usman M, Waheed KAI, Rauf K. Multidrug resistant microorganisms causing neonatal septicemia: in a tertiary care hospital Lahore, Pakistan. Afr J Microbiol Res. 2013;7:1896–902.
45.
Hussain M, Hasan F, Shah AA, Hameed A, Jung M, Rayamajhi N, Cha S-B, Yoo HS. Prevalence of class a and Ampc β-Lactamases in clinical Escherichia coli isolates from Pakistan Institute of Medical Science, Islamabad, Pakistan. Jpn J Infect Dis. 2011;64:249–52.PubMed
46.
Kausar A, Akram M, Shoaib M, Mehmood RT, Abbasi MN, Muhammad A, Aziz H, Asad MJ. Isolation and identification of UTI causing agents and frequency of ESBL (extended Spectrum β-Lactamase) in Pakistan. Amer JPhytomed Clin Ther. 2014;2:963–75.
47.
Ali A, Rafi S, Qureshi A. Frequency of extended spectrum β-lactamase producing gram negative bacilli among clinical isolates at clinical laboratories of Army medical college, Rawalpindi. PRO. 2004;2:25–9.
48.
Begum S, Hasan F, Hussain S, Shah AA. Prevalence of multidrug-resistant Acinetobacter Baumannii in the clinical samples from tertiary care hospital in Islamabad, Pakistan. Pak J Med Sci. 2013;29:1253–8.PubMedPubMedCentral
49.
Ullah F, Malik SA, Ahmed J. Antibiotic susceptibility pattern and ESBL prevalence in nosocomial Escherichia coli from urinary tract infections in Pakistan. Afric J Biotechnol. 2009;8:3921–6.
50.
Rahman H, Naeem M, Khan I, Khan J, Haroon M, Bari F, Ullah R, Qasim M. Molecular prevalence and antibiotics resistance pattern of class a bla CTX-M-1 and bla TEM-1 β- Lactamases in uropathogenic Escherichia coli isolates from Pakistan. Turk J Med Sci. 2016;46:897–902.PubMed
51.
Zhang J, Zheng B, Zhao L, Wei Z, Ji J, Li L, Xiao Y. Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitals. BMC Infect Dis. 2014;14:659–63.PubMedPubMedCentral
52.
Sonda T, Kumburu H, van Zwetselaar M, Alifrangis M, Lund O, Kibiki G, Aarestrup FM. Meta-analysis of proportion estimates of extended-spectrum-β-lactamase-producing Enterobacteriaceae in East Africa hospitals. Antimicrob Resis Infect Control. 2016;5:18–26.
53.
Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012;27:128–42.PubMedPubMedCentral
54.
Leistner R, Schröder C, Geffers C, Breier A-C, Gastmeier P, Behnke M. Regional distribution of nosocomial infections due to ESBL-positive Enterobacteriaceae in Germany: data from the German national reference center for the surveillance of nosocomial infections (KISS). Clin Microbiol Infect. 2015;21:255.
55.
Flamm RK, Sader HS, Farrell DJ, Jones RN. Ceftaroline potency among 9 US census regions: report from the 2010 AWARE program. Clin Infect Dis. 2012;55:S194–205.PubMed
56.
Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversityof β-Lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2014;58:833-838.
57.
Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G, Group IES. Occurrence of extended-Spectrum β-Lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother. 2002;46:196–202.PubMedPubMedCentral
58.
Mahmood K, Izhar M, Choudhry N, Mujtaba G, Rashid N. Emergence of extended-spectrum-lactamase producing Salmonella Typhi in Pakistan. Afric J Microbiol Res. 2012;6:793–7.
59.
Ahmad M, Hassan M, Khalid A, Tariq I, Asad MHHB, Samad A, Mahmood Q, Murtaza G. Prevalence of extended spectrum β-lactamase and antimicrobial susceptibility pattern of clinical isolates of Pseudomonas from patients of Khyber Pakhtunkhwa, Pakistan. Biomed Res Int. 2016:2016–26.
60.
Lonchel CM, Meex C, Gangoué-Piéboji J, Boreux R, Assoumou M-CO, Melin P, De Mol P. Proportion of extended-spectrum ß-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon. BMC Infect Dis. 2012;12:53–9.PubMedPubMedCentral
61.
Bourjilat F, Bouchrif B, Dersi N, Claude JDPG, Amarouch H, Timinouni M. Emergence of extended-spectrum beta-lactamases-producing Escherichia coli in community-acquired urinary infections in Casablanca, Morocco. J Infect Dev Ctries. 2011;5:850–5.PubMed
62.
Muvunyi CM, Masaisa F, Bayingana C, Mutesa L, Musemakweri A, Muhirwa G. Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines. Am J Trop Med Hyg. 2011;84:923–8.PubMedPubMedCentral
63.
Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in non-hospitalized patients. Euro J Clin Microbiol Infect Dis. 2004;23:163–7.
64.
Tandé D, Jallot N, Bougoudogo F, Montagnon T, Gouriou S, Sizun J. Extended-spectrum β-lactamase–producing Enterobacteriaceae in a Malian orphanage. Emerg Infect Dis. 2009;15:472–4.PubMedPubMedCentral
65.
Valverde A, Coque TM, Sánchez-Moreno MP, Rollán A, Baquero F, Cantón R. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during non-outbreak situations in Spain. J Clin Microbiol. 2004;42:4769–75.PubMedPubMedCentral
66.
Ho P, Poon WW, Loke S, Leung MS, Chow K, Wong RC, Yip K, Lai EL, Tsang KW. Community emergence of CTX-M type extended-spectrum β-lactamases among urinary Escherichia coli from women. J Antimicrob Chemother. 2007;60:140–4.PubMed
67.
Rodríguez-Bano J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pérez-Cano R. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in non-hospitalized patients. J Clin Microbiol. 2004;42:1089–94.PubMedPubMedCentral
68.
Kader A, Kamath K. Faecal carriage of extended-spectrum beta-lactamase-producing bacteria in the community. East Mediterr Health J. 2009;15:1365–70.PubMed
69.
Day KM, Ali S, Mirza IA, Sidjabat HE, Silvey A, Lanyon CV, Cummings SP, Abbasi SA, Raza MW, Paterson DL. Prevalence and molecular characterization of Enterobacteriaceae producing NDM-1 carbapenemase at a military hospital in Pakistan and evaluation of two chromogenic media. Diagnostic Microbiol Infect Dis. 2013;75:187–91.
70.
Sheng W-H, Badal RE, Hseuh P-R. Distribution of extended-spectrum β-lactamases (ESBLs), Ampc β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in Asia-Pacific: the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother. 2013;57:2981-2988.
71.
Lahlaoui H, Khalifa ABH, Moussa MB. Epidemiology of Enterobacteriaceae producing CTX-M type extended spectrum β-lactamase (ESBL). Mede Malad Infect. 2014;44:400–4.
72.
Altinkum SM, Ergin S, Bahar H, Torun MM. CTX-M-15 type extended spectrum-lactamase producing Escherichia coli and Klebsiella pneumoniae: a developing problem in infected outpatients and hospitalised patients in Istanbul, Turkey. African J Microbiol Res. 2013;7:692–7.
73.
Chandramohan L, Revell PA. Prevalence and molecular characterization of extended-spectrum-β-lactamase-producing Enterobacteriaceae in a pediatric patient population. Antimicrob Agents Chemother. 2012;56:4765–70.PubMedPubMedCentral
74.
Winokur P, Canton R, Casellas J-M, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the western Pacific region. Clin Infect Dis. 2001;32:94–103.
75.
Winokur P, Canton R, Casellas J-M, Legakis N. Regional variation in the prevalence of extended-spectrum β-lactamase–producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diag Microbiol Infect Dis. 2005;52:323–9.
76.
Shah S. Susceptibility patterns of Escherichia coli: prevalence of multidrug-resistant isolates and extended spectrum β-lactamase phenotype. J Pak Med Assoc. 2002;52:132–8.
77.
Shah AA, Hasan F, Ahmed S, Hameed A. Prevalence of extended-spectrum β-lactamases in nosocomial and out-patients (ambulatory). Pak J Med Sci. 2003;19:187–91.
78.
Mumtaz S, Ahmad M, Aftab I, Akhtar N, Hassan M, Hamid A. Extended spectrum β-lactamases in enteric gram-negative bacilli: related to age and gender. J Ayub Med Coll Abbott. 2007;19:107–11.
79.
Khan E, Schneiders T, Zafar A, Aziz E, Parekh A, Hasan R. Emergence of CTX-M group 1-ESBL producing Klebsiella pneumonia from a tertiary care centre in Karachi, Pakistan. J Infect Dev Countr. 2010;4:472–6.
80.
Roshan M, Ikram A, Mirza IA, Malik N, Abbasi SA, Alizai SA. Susceptibility pattern of extended spectrum ß-lactamase producing isolates in various clinical specimens. J Coll Physicians Surg Pak. 2011;21:342–6.PubMed
81.
Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M. Frequency and antibiotic susceptibility pattern of amp C β-lactamase producing bacteria isolated from a tertiary care hospital of Rawalpindi, Pakistan. Pak J Med Sci. 2011;27:578–81.
82.
Habeeb MA, Haque A, Nematzadeh S, Iversen A, Giske CG. Rapid emergence of ESBL producers in E. coli causing urinary and wound infections in Pakistan. Pak J Med Sci. 2013;29:540–4.PubMedPubMedCentral
83.
Khalid A, Usman J, Kaleem F, Hassan A, Omair M, Anjum R. The frequency and antimicrobial sensitivity pattern of extended spectrum-lactamase (ESBLs) producing gram negative bacilli isolated from urine in a tertiary care hospital of Pakistan. Afric J Microbiol Res. 2013;7:2040–3.
84.
Sabir S, Anjum AA, Ijaz T, Ali MA, Rehman MU, Nawaz M. Isolation and antibiotic susceptibility of E. coli from urinary tract infections in a tertiary care hospital. Pak J Med Sci. 2014;30:389–92.PubMedPubMedCentral
85.
Saboor MAM, Waheed U, Anwarullah, Umar M. Prevalence of ESBL producing Enterobacteriaceae in a private hospital in Islamabad. Int J Rehab Sci. 2014;3:18–22.
86.
Sohail M, Khurshid M, Saleem HGM, Javed H, Khan AA. Characteristics and antibiotic resistance of urinary tract pathogens isolated from Punjab, Pakistan. Jundishapur J Microbiol. 2015;8:e19272.PubMedPubMedCentral
87.
Ahmed I, Sajed M, Sultan A, Murtaza I, Yousaf S, Maqsood B, Vanhara P, Anees M. The erratic antibiotic susceptibility patterns of bacterial pathogens causing urinary tract infections. EXCLI J. 2015;14:916.PubMedPubMedCentral
88.
Jamil B, Bokhari MTM, Saeed A, Bokhari MZM, Hussain Z, Khalid T, Bukhari H, Imran M, Abbasi SA. Bacteremia: prevalence and antimicrobial resistance profiling in chronic kidney diseases and renal transplant patients. J Pak Med Assoc. 2016;66:705.PubMed
89.
Anwar M, Ejaz H, Zafar A, Hamid H. Phenotypic detection of metallo-β-lactamases in carbapenem resistant Acinetobacter baumannii isolated from pediatric patients in Pakistan. J Pathog. 2016;2016:1–6.
90.
Mumtaz S, Ahmed J, Ali L, Hussain H. Prevalence of extended spectrum β-lactamases (ESBL) in clinical isolates from a teaching hospital in Peshawar, Pakistan. Afric J Microbiol Res. 2011;5:2880–4.
91.
Iqbal R, Majid A, Alvi IA, Hayat A, Andaleeb F, Gul S, Irfan S, Rahman MU. Multiple drug resistance and ESBL production in bacterial urine culture isolates. Amer J Biosci. 2014;2:5–12.
92.
Jabeen K, Zafar A, Hasan R. Comparison of double disc and combined disc method for the detection of extended spectrum ß-lactamases in Enterobacteriaceae. J Pak Med Asso. 2003;53:534–7.
93.
Jabeen K, Znfar A, Hasan R. Frequency and sensitivity pattern of extended spectrum β-lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc. 2005;55:436.PubMed
94.
Ahmed E, Durrani M, Qamar S, Kharal S. Detection of extended spectrum β-lactamase (ESBL) producing organisms in Enterobacteriaceae Family like Escherichia coli (E. coli) and Klebsiella pneumoniae by double disc diffusion method (DDDM). Pak J Pharmacol. 2009;26:25–30.
95.
Jabeen K, Zafar A, Irfan S, Khan E, Mehraj V, Hasan R. Increase in isolation of extended spectrum beta lactamase producing multidrug resistant non typhoidal Salmonellae in Pakistan. BMC Infect Dis. 2010;10:101–6.PubMedPubMedCentral
96.
Khan E, Ejaz M, Zafar A, Jabeen K, Shakoor S, Inayat R, Hasan R. Increased isolation of ESBL producing Klebsiella pneumoniae with emergence of carbapenem resistant isolates in Pakistan: report from a tertiary care hospital. J Pak Med Assoc. 2010;60:186–9.PubMed
97.
Afridi, F.I., B.J. Farooqi, And A. Hussain, Frequency of extended spectrum beta lactamase producing Enterobacteriaceae among urinary pathogen isolates. J Coll Physicians Surg Pak. 2011;21:741-744.PubMed
98.
Hassan SA, Jamal SA, Kamal M. Occurrence of multidrug resistant and ESBL producing E. coli causing urinary tract infections. J Basic Appl Sci. 2011;7:39–43.
99.
Afridi FI, Farooqi BJ. Activity of β-lactam β-lactamase inhibitor combinations against extended spectrum β-lactamase producing Enterobacteriaceae in urinary isolates. J Coll Physicians Surg Pak. 2012;22:358–62.PubMed
100.
Ullah F, Malik SA, Ahmed J. Antimicrobial susceptibility and ESBL prevalence in Pseudomonas aeruginosa isolated from burn patients in the north-west of Pakistan. Burns. 2009;35:1020–5.PubMed
101.
Mirza SH, Salman M, Khurshid U, Wiqar MA. CTX-M ESBL enzyme in Escherichia coli from urology patients in Rawalpindi, Pakistan. J Pak Med Assoc. 2006;56:576–80.PubMed
Metadata
Title
Prevalence of extended-spectrum-β-lactamase-producing Enterobacteriaceae: first systematic meta-analysis report from Pakistan
Authors
Samyyia Abrar
Shahida Hussain
Rehan Ahmad Khan
Noor Ul Ain
Hayat Haider
Saba Riaz
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2018
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-018-0309-1

Other articles of this Issue 1/2018

Antimicrobial Resistance & Infection Control 1/2018 Go to the issue

Research

An observational case study of hospital associated infections in a critical care unit in Astana, Kazakhstan

Short report

Colonization sites in carriers of ESBL-producing Gram-negative bacteria

Research

The acceptability of screening for Carbapenemase Producing Enterobacteriaceae (CPE): cross-sectional survey of nursing staff and the general publics’ perceptions

Research

Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study

Research

Factors associated with bacteraemia due to multidrug-resistant organisms among bacteraemic patients with multidrug-resistant organism carriage: a case control study

Research

Risk for subsequent infection and mortality after hospitalization among patients with multidrug-resistant gram-negative bacteria colonization or infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits